Imprimis Pharma (IMMY) Reports Q3 Loss of $0.29/Share

Imprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.29), versus ($0.41) reported last year. Revenue for the quarter came in at $4.9 million, versus $2.7 million reported last year.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026
• Raymond James sees positive earnings trends across market caps